PCR-based assays for the identification of Neisseria meningitidis serogroups 29E, X, and Z by detection of specific regions of the ctrA gene are described. The specificities of these assays were confirmed using serogroups A, B, C, 29E, H, W135, X, Y, and Z and nongroupable meningococcal isolates.
verse primer ( Table 1) described by Corless et al. (4) and demonstrated to amplify a region of the ctrA gene from all meningococcal serogroups (4, 11) .
The specificity of these primers in amplifying the ctrA target from different meningococcal serogroups was tested by PCR. All meningococcal strains used were isolated from cases of disease or during a carriage survey (unpublished data). The serogroup of each isolate was determined by coagglutination and/or by direct slide agglutination. For each serogroup, separate PCRs were performed in 50-l volumes comprising 1 U of Taq DNA polymerase (Gibco-BRL/Life Technologies), 2.5 mM MgCl 2 , 5 l of 10ϫ buffer (1ϫ buffer contains 10 mM Tris HCl [pH 9 at 25°C], 50 mM KCl, 0.1% Triton X-100), 1.5 mM (each) forward and reverse primer, and 0.2 mM deoxynucleoside triphosphates (dATP, dGTP, dCTP, and dTTP), to which 1 l of purified N. meningitidis DNA (100 to 300 ng) (Puregene DNA isolation kit; Gentra Systems, Minneapolis, Minn.) was added. Amplifications were carried out on a PTC 200 DNA Engine (MJ Research) thermal cycler, using the same parameters irrespective of serogroup, and involved, after an initial cycle of 95°C for 5 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 62.5°C for 1 min, and extension at 72°C for 30 s. Following amplification, all reaction mixes were held at 4°C until 5 l of reaction mix was analyzed on a 3.5% (wt/vol) agarose gel containing 0.5 g of ethidium bromide/ml and viewed using UV light.
Amplification products of 667 bp were observed for serogroups 29E (primer ctrA 29EF2) and Z (primer ctrA ZF), and a product of 525 bp was observed for serogroup X (primer ctrA XF3). No cross-reactions were observed between the specific forward primer and isolates of either of the other serogroups or for representative strains of serogroups B, C, H, W135, and Y (including 10 serogroup B strains, 10 serogroup C strains, 2 serogroup H strains, 5 serogroup W135 strains, and 5 serogroup Y strains). With the ctrA XF3 primer, products were detected in two serogroup A strains but were of a different size (approximately 650 bp) from that observed with serogroup X strains. Compared to conventional serologic grouping, the assays correctly identified 12 of 12 serogroup X isolates, 4 of 4 serogroup Z isolates, and 2 of 2 serogroup 29E isolates. Therefore, the specificity of these primers for grouping strains of these serogroups was 100%.
To further evaluate these assays, we applied them to 37 Each of these isolates contained the ctrA gene. Of the 37, 11 yielded a product with the ctrA XF3/ctrA UR primers, 6 yielded a product with the ctrA ZF/ctrA UR primers, and 19 yielded a product with the ctrA 29EF2/ctrA UR primers. The three primer pairs failed to generate an amplification product with only 1 isolate; presumably this isolate represented another uncommon serogroup, for instance, serogroup I, K, or L (for which there are no antisera available). This report demonstrates that these assays reliably distinguish meningococcal serogroups 29E, X, and Z from other serogroups, with the major benefit of identifying these among previously nongroupable isolates. Used in conjunction with the already available PCR-based identification assays (6, 8, 15) , these new assays allow the characterization of all meningococcal serogroups currently known to be associated with disease and/or carriage worldwide. Furthermore, since these assays are PCR based, they could be applied to clinical samples for diagnostic purposes.
Although few cases of disease have been reported with these serogroups, temporal changes in disease-associated serogroups are well documented (23); hence, they may emerge as significant pathogens. Characterization of meningococci according to serogroup is important given that most available meningococcal vaccines are capsular polysaccharide based (18) . The exact effects of widespread immunization as far as inducing changes in the population structure of meningococci are unknown, but it is likely to affect the phenomenon of capsule switching and also to select for strains of serogroups previously considered to be of limited pathogenicity, such as serogroups 29E, X, and Z (20, 24) . It is probable that the observed replacement of serogroup A strains by serogroup X strains colonizing and causing disease in northern Ghana was a direct effect of the mass A/C polysaccharide vaccination campaigns of 1997 and 1998 (7). The emergent serogroup X strains were closely related to serogroup X strains already present but at a much lower abundance. For precisely this reason, the serogroups of all circulating meningococci should be identified and monitored, especially in countries in which widespread meningococcal vaccination has been introduced. 
